Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Italy
Italy: Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage was 90.0% in 2024. ▲ Rising
Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Italy, 2008–2024
Source: WHO & UNICEF (2025); UN, World Population Prospects (2024) – processed by Our World in Data. Measured in %.
Analysis
The most recent figure for pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Italy is 90.0%, measured in 2024.
The figure is down 2.2% on the previous year and up 3.4% over ten years.
Over the whole period, pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Italy peaked at 92.0% in 2018 and was at its lowest, 60.0%, in 2008.
That places Italy 64th out of 146 countries with data for 2024, putting it in the middle of the range.
The long-run direction has been consistently rising across the 17 years of available data.
Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Italy, year by year
| Year | % | Change |
|---|---|---|
| 2008 | 60.0% | — |
| 2009 | 66.0% | +10.0% |
| 2010 | 71.0% | +7.6% |
| 2011 | 76.0% | +7.0% |
| 2012 | 82.0% | +7.9% |
| 2013 | 87.0% | +6.1% |
| 2014 | 87.0% | +0.0% |
| 2015 | 89.0% | +2.3% |
| 2016 | 88.0% | -1.1% |
| 2017 | 91.0% | +3.4% |
| 2018 | 92.0% | +1.1% |
| 2019 | 92.0% | +0.0% |
| 2020 | 91.0% | -1.1% |
| 2021 | 91.0% | +0.0% |
| 2022 | 92.0% | +1.1% |
| 2023 | 92.0% | +0.0% |
| 2024 | 90.0% | -2.2% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 63.0% | 60.0% | 66.0% | 2 |
| 2010s | 85.5% | 71.0% | 92.0% | 10 |
| 2020s | 91.2% | 90.0% | 92.0% | 5 |
Countries ranked near Italy
More health data for Italy
- Un projection of annual infant deaths, annual growth rate -2.44 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.1206 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,408 deaths per 1,000 people (2090)
- Number of infants who die before age 1 80 deaths (2100)
- Population ages 0-14, female, annual growth rate -2.05 % change on previous year (2025)
- Population ages 0-14, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 0-14, female, per capita 0.0566 units per person (2025)
- Population ages 0-14, male, annual growth rate -2.02 % change on previous year (2025)
- Population ages 0-14, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 0-14, male, per capita 0.0599 units per person (2025)
Frequently asked questions
- What is pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Italy?
- Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Italy was 90.0% in 2024, according to WHO & UNICEF (2025); UN, World Population Prospects (2024) – processed by Our World in Data.
- What is the highest pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage recorded in Italy?
- The highest recorded value was 92.0% in 2018.
- What is the lowest pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage recorded in Italy?
- The lowest recorded value was 60.0% in 2008.
- How does Italy rank for pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage?
- Italy ranks 64th out of 146 countries with data for 2024.
- Is pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage rising or falling in Italy?
- Over the last ten years it is up 3.4%. The long-run trend across the full record is rising.
- Where does this Italy data come from?
- The figures come from WHO & UNICEF (2025); UN, World Population Prospects (2024) – processed by Our World in Data, published as part of Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 17 observations, free to reuse under CC BY 4.0 (Our World in Data).
About this data
Share of one-year-olds who have had the third dose of the pneumococcal conjugate vaccine in a given year.